Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and
safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with
essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and < 110
mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted
to support registration of the fixed-dose combination of aliskiren and amlodipine for the
treatment of hypertension in Japan.